The DOI matches its Crossref record.
Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia
Abstract
Cellular immunophenotypic studies were performed on a cohort of randomly selected IgM+ B-chronic lymphocytic leukemia (B-CLL) cases for which Ig VH and VL gene sequences were available. The cases were categorized based on V gene mutation status and CD38 expression and analyzed for treatment history and survival. The B-CLL cases could be divided into 2 groups. Those patients with unmutated V genes displayed higher percentages of CD38+ B-CLL cells (≥30%) than those with mutated V genes that had lower percentages of CD38+ cells (<30%). Patients in both the unmutated and the ≥30% CD38+ groups responded poorly to continuous multiregimen chemotherapy (including fludarabine) and had shorter survival. In contrast, the mutated and the <30% CD38+ groups required minimal or no chemotherapy and had prolonged survival. These observations were true also for those patients who stratified to the Rai intermediate risk category. In the mutated and the <30% CD38+ groups, males and females were virtually equally distributed, whereas in the unmutated and the ≥30% CD38+ groups, a marked male predominance was found. Thus, Ig V gene mutation status and the percentages of CD38+B-CLL cells appear to be accurate predictors of clinical outcome in B-CLL patients. These parameters, especially CD38 expression that can be analyzed conveniently in most clinical laboratories, should be valuable adjuncts to the present staging systems for predicting the clinical course in individual B-CLL cases. Future evaluations of new therapeutic strategies and drugs should take into account the different natural histories of patients categorized in these manners.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Chiorazzi, N., Rai, K. R., & Ferrarini, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041720 · Cited by 1,296
Self-citationCrespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D., Rozman, M., Marcé, S., López-Guillermo, A., Campo, E., & Montserrat, E. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa023143 · Cited by 1,055
Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology
Malavasi, F., Deaglio, S., Funaro, A., Ferrero, E., Horenstein, A. L., Ortolan, E., Vaisitti, T., & Aydin, S. (2008) · Physiological Reviews · doi:10.1152/physrev.00035.2007 · Cited by 862
Rassenti, L. Z., Huynh, L., Toy, T. L., Chen, L., Keating, M. J., Gribben, J. G., Neuberg, D. S., Flinn, I. W., Rai, K. R., Byrd, J. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040857 · Cited by 745
Self-citationRole of Bruton’s tyrosine kinase in B cells and malignancies
Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726
ZAP-70 expression and prognosis in chronic lymphocytic leukaemia.
Orchard, J. A., Ibbotson, R. E., Davis, Z., Wiestner, A., Rosenwald, A., Thomas, P. W., Hamblin, T. J., Staudt, L. M., & Oscier, D. G. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15260-9 · Cited by 448
Targeting B cell receptor signalling in cancer: preclinical and clinical advances
Burger, J. A., & Wiestner, A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.121 · Cited by 431
Chen, L., Widhopf, G., Huynh, L., Rassenti, L., Rai, K. R., Weiss, A., & Kipps, T. J. (2002) · Blood · doi:10.1182/blood-2002-06-1683 · Cited by 426
Self-citationMonoclonal antibodies targeting CD 38 in hematological malignancies and beyond
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353
Deckert, J., Wetzel, M.-C., Bartle, L. M., Skaletskaya, A., Goldmacher, V. S., Vallée, F., Zhou-Liu, Q., Ferrari, P., Pouzieux, S., Lahoute, C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0695 · Cited by 333
B cell receptor signaling in chronic lymphocytic leukemia
Burger, J. A., & Chiorazzi, N. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.002 · Cited by 327
Self-citationGobessi, S., Laurenti, L., Longo, P. G., Carsetti, L., Berno, V, Sica, S., Leone, G., & Efremov, D. G. (2009) · Leukemia · doi:10.1038/leu.2008.346 · Cited by 200
CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment.
Patten, P. E. M., Buggins, A. G. S., Richards, J., Wotherspoon, A., Salisbury, J., Mufti, G. J., Hamblin, T. J., & Devereux, S. (2008) · Blood · doi:10.1182/blood-2007-08-108605 · Cited by 196
Liu, T.-M., Woyach, J. A., Zhong, Y., Lozanski, A., Lozanski, G., Dong, S., Strattan, E., Lehman, A., Zhang, X., Jones, J. A., et al. (2015) · Blood · doi:10.1182/blood-2015-02-626846 · Cited by 178
Yan, X.-J., Albesiano, E., Zanesi, N., Yancopoulos, S., Sawyer, A., Romano, E., Petlickovski, A., Efremov, D. G., Croce, C. M., & Chiorazzi, N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604564103 · Cited by 149
Self-citationRendeiro, A. F., Schmidl, C., Strefford, J. C., Walewska, R., Davis, Z., Farlik, M., Oscier, D., & Bock, C. (2016) · Nature Communications · doi:10.1038/ncomms11938 · Cited by 146
Molecular and cellular mechanisms of CLL: novel therapeutic approaches.
Pleyer, L., Egle, A., Hartmann, T. N., & Greil, R. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.72 · Cited by 125
Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia
Ronchetti, D., Mosca, L., Cutrona, G., Tuana, G., Gentile, M., Fabris, S., Agnelli, L., Ciceri, G., Matis, S., Massucco, C., et al. (2013) · BMC Medical Genomics · doi:10.1186/1755-8794-6-27 · Cited by 91
Self-citationSong, Z., Lu, P., Furman, R. R., Leonard, J. P., Martin, P., Tyrell, L., Lee, F. Y., Knowles, D. M., Coleman, M., & Wang, Y. L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1519 · Cited by 59
Poly(ADP-Ribose) Polymerases in Host-Pathogen Interactions, Inflammation, and Immunity
Brady, P. N., Goel, A., & Johnson, M. A. (2019) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00038-18 · Cited by 58
Reiniger, L., Bödör, C., Bognár, Á., Balogh, Z., Csomor, J., Szepesi, Á., Kopper, L., & Matolcsy, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404183 · Cited by 54
Integration of innate into adaptive immune responses in ZAP-70–positive chronic lymphocytic leukemia
Wagner, M., Oelsner, M., Moore, A., Götte, F., Kuhn, P.-H., Haferlach, T., Fiegl, M., Bogner, C., Baxter, E. J., Peschel, C., et al. (2016) · Blood · doi:10.1182/blood-2015-05-646935 · Cited by 29
Lanasa, M. C., Davis, P. H., Datto, M., Li, Z., Gockerman, J. P., Moore, J. O., DeCastro, C. M., Friedman, D. R., Diehl, L. F., Rehder, C., et al. (2012) · Leukemia & Lymphoma · doi:10.3109/10428194.2011.610012 · Cited by 16
Metadata
- Authors
- Damle, R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S. L., Buchbinder, A., Budman, D., Dittmar, K., Kolitz, J., Lichtman, S. M., Schulman, P., Vinciguerra, V. P., Rai, K. R., Ferrarini, M., & Chiorazzi, N.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1999-09-15
- Volume
- 94
- Issue
- 6
- Pages
- 1840-1847
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1243376384
- Cited by
- 2,642
- References
- 0
- FWCI
- 42.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
